Brokerages Set Geron Co. (NASDAQ:GERN) Target Price at $7.25

Geron Co. (NASDAQ:GERN) has earned a consensus rating of “Buy” from the twelve analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, nine have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $6.91.

GERN has been the topic of several research reports. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Geron in a research note on Tuesday, December 10th. B. Riley reduced their target price on shares of Geron from $5.50 to $3.50 and set a “buy” rating for the company in a report on Tuesday. Needham & Company LLC raised their target price on shares of Geron from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, Barclays raised shares of Geron to a “strong-buy” rating in a research report on Friday, November 29th.

Institutional Trading of Geron

Several institutional investors and hedge funds have recently bought and sold shares of GERN. SBI Securities Co. Ltd. bought a new stake in Geron in the 4th quarter valued at $28,000. Integrated Wealth Concepts LLC bought a new position in shares of Geron in the fourth quarter valued at about $36,000. GF Fund Management CO. LTD. bought a new position in shares of Geron in the fourth quarter valued at about $45,000. Fifth Lane Capital LP acquired a new stake in shares of Geron during the 4th quarter worth about $53,000. Finally, Readystate Asset Management LP bought a new stake in shares of Geron during the 3rd quarter worth about $58,000. Institutional investors own 73.71% of the company’s stock.

Geron Stock Performance

GERN opened at $2.58 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -8.05 and a beta of 0.53. The business’s 50-day moving average price is $3.11 and its two-hundred day moving average price is $3.87. Geron has a 1 year low of $1.64 and a 1 year high of $5.34.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.